SIBO Is Not New: What 60 Years of Clinical History Can Teach Us

Small intestinal bacterial overgrowth, usually shortened to SIBO, is often discussed as though it emerged with the modern microbiome movement. The terminology may feel new, but the underlying clinical problem is not. Physicians have been studying the consequences of misplaced intestinal bacteria for decades, especially in patients with severe liver disease and other well-defined gastrointestinal conditions.

In the source video, Dr. Patrick Nemechek uses that history to make a practical point: bacterial overgrowth can appear under different diagnostic labels because the organisms involved, the compounds they produce, and the patient’s underlying condition are different. His interpretation is broader than conventional definitions in several places, so it is important to separate the established history of bacterial overgrowth from the clinical framework he applies to conditions such as IBS with diarrhea and autism.

SIBO is an organizational problem

The small intestine and colon are not interchangeable environments. They normally contain different concentrations and communities of microorganisms. Dr. Nemechek explains this with a memorable analogy: “birds” belong in the small intestine and “fish” belong in the colon.

In that analogy, SIBO occurs when too many “fish”—bacteria normally associated with the colon—are living in the small intestine. These are not necessarily dangerous organisms acquired from contaminated food. They may be ordinary members of the intestinal microbiome that are present in the wrong location or in abnormal numbers.

That distinction matters. Calling every organism “good” or “bad” misses the role of location. A bacterium that is well tolerated in the colon can cause problems when it becomes abundant farther upstream, where digestion and nutrient absorption are taking place.

What 60 years of clinical history can teach us

Dr. Nemechek points to several older medical contexts to show that bacterial overgrowth is not a recent discovery. These conditions are not identical, and they should not be treated as interchangeable diagnoses. They do, however, illustrate how intestinal bacteria and their metabolic products have long been clinically important.

Advanced liver disease and hepatic encephalopathy

One of the clearest historical examples involves people with severely impaired liver function. Intestinal bacteria can produce ammonia, while a damaged liver may be less able to clear it from circulation. Rising ammonia and related metabolic disturbances can contribute to hepatic encephalopathy, a potentially life-threatening decline in brain function.

Dr. Nemechek notes that intestinal bacterial management in this setting has been studied for decades. He highlights rifaximin, a minimally absorbed antibiotic that may be used long term under medical supervision to reduce the risk of recurrent hepatic encephalopathy. This is a specialist-managed use in patients with serious liver disease—not a reason for a reader to self-diagnose SIBO or seek antibiotics without evaluation.

In the video below, Dr. Nemechek explains how this history informs his broader view of bacterial overgrowth.

Clostridioides difficile and toxin-producing overgrowth

Dr. Nemechek also discusses Clostridioides difficile infection, historically called Clostridium difficile. This organism can proliferate after disruption of the intestinal ecosystem and produce toxins that cause severe colitis. In the video, he groups this with other examples of organisms becoming overabundant and producing clinically important chemicals.

C. difficile infection is a specific infectious disease with established diagnostic and treatment pathways. It should not be treated as a synonym for ordinary SIBO. The useful historical lesson is narrower: medicine has long recognized that the location, abundance, and metabolic activity of intestinal bacteria can have consequences far beyond a simple upset stomach.

IBS with diarrhea and bacterial overgrowth

Dr. Nemechek describes cramping and diarrhea in some people with IBS-D as another presentation of bacterial overgrowth. Research and clinical guidelines recognize overlap between IBS symptoms and SIBO, but the two labels are not automatically equivalent for every patient. Diarrhea can have many causes, including infection, inflammatory bowel disease, medication effects, food intolerance, and other disorders.

That is why symptoms alone cannot establish which bacteria are present or where the problem originates. The history may make bacterial overgrowth a reasonable question, but diagnosis still requires an individualized clinical assessment.

How Dr. Nemechek extends the framework to autism

The most controversial part of the video is Dr. Nemechek’s application of bacterial-overgrowth physiology to autism. He proposes that, in some children, intestinal bacteria produce excess propionic acid and that this bacterial metabolite can influence behavior and neurological function.

He traces part of this idea to microbiologist Dr. Sidney Finegold and a small 2000 study of oral vancomycin in 11 children with regressive-onset autism. Eight children were reported to have short-term behavioral improvement during treatment, followed by loss of much of that improvement after the antibiotic was stopped. The study was small and was not designed to establish bacterial overgrowth as a universal cause of autism. Dr. Nemechek presents it as an important clue that helped shape his clinical hypothesis and treatment framework.

Readers who want the broader gut-brain context can continue with Gut Dysbiosis and the Brain, which explains how the existing Journal approaches intestinal balance, inflammation, and neurodevelopment.

One mechanism can produce different clinical consequences

The enduring insight is not that hepatic encephalopathy, C. difficile infection, IBS-D, and autism are the same disease. They are not. The insight is that bacteria produce biologically active compounds, and the clinical result depends on the organism, its location, the compounds being produced, and the patient’s ability to process or respond to them.

That history also argues against using “microbiome” as a vague explanation for every symptom. A useful bacterial-overgrowth model must specify what is believed to be happening, what evidence supports it, and whether the statement reflects established medicine, emerging research, or a clinician’s interpretation.

Use a structured resource for the next questions

SIBO questions often become confusing because symptoms, testing, gut motility, medications, and inflammation overlap. Explore the Nemechek Navigator for organized educational resources and tools that help families understand the Nemechek Protocol framework and track questions over time.

Medical note: This article is educational and summarizes historical examples alongside Dr. Nemechek’s clinical interpretations. It does not diagnose SIBO, autism, liver disease, IBS, or an intestinal infection, and it does not replace care from a qualified healthcare professional. Seek prompt medical attention for confusion, severe or persistent diarrhea, dehydration, blood in the stool, fever, or rapidly worsening symptoms.